David Hsiehchen

Jan 14, 2025 | sciencedirect.com | Habib Hamidi |Romain Banchereau |David Hsiehchen |Hao Yue Zhu

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has transformed the treatment of refractory B cell non-Hodgkin’s lymphomas (B-NHL), including diffuse large B cell lymphoma (DLBCL) and multiply relapsed follicular lymphoma (FL).1,2,3,4,5 However, only 30%–40% of DLBCL and FL patients maintain durable complete remission after five years.6,7,8,9,10,11,12 The reasons behind such variable outcomes remain enigmatic, and cellular immunotherapies are currently administered without...

Nov 21, 2024 | cell.com | David Hsiehchen |Andrew Elliott |Joanne Xiu |Andreas Seeber |Wafik El-Deiry |Emmanuel S. Antonarakis | +12 more

1Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA2Harold C.

Mar 10, 2024 | nature.com | David Hsiehchen |Rolf A. Brekken |Amit Singal |Hao Yue Zhu |Yujin Hoshida |Courtney Katz

AbstractImmune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a single-arm phase 2 trial evaluating frontline bavituximab, a phosphatidylserine targeting antibody, plus pembrolizumab (anti-PD-1) in patients with unresectable hepatocellular carcinoma (NCT03519997).

Nov 22, 2023 | nature.com | David Hsiehchen

Correction to: Nature Communications; https://doi.org/10.1038/s41467-022-35144-1; Article published online 03 December 2022The original version of this Article contained an error in the Supplementary Information file, in which Supplementary Figures 15 and 16 were mistakenly included. These figures were replaced by Supplementary Table 1 during revision. The HTML has been updated to include a corrected version of the Supplementary Information.